{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:49:31Z","timestamp":1784562571825,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>We aimed to assess temporal trends in outcomes of ST-elevation myocardial infarction (STEMI) patients with diabetes and heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) and compared both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from the National Inpatient Sample was analyzed between 2005 and 2017. We assessed hospitalizations rate and in-hospital mortality, ventricular tachycardia (VT), ventricular fibrillation (VF), atrial fibrillation (AF), cardiogenic shock (CS), ischemic stroke, acute renal failure (ARF), and revascularization strategy. Socio-economic outcomes consisted of the length of stay (LoS) and total charges\/stay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hospitalization rate steadily decreased with time in STEMI patients with diabetes and HFrEF. Mean age (SD) decreased from 71 \u00b1 12 to 67 \u00b1 12 (<jats:italic>p<\/jats:italic> &amp;lt; 0.01), while the prevalence of comorbidities increased. Mortality was stable (around 9%). However, VT, VF, AF, CS, ischemic stroke, and ARF significantly increased with time. In STEMI patients with HFpEF and diabetes, the hospitalization rate significantly increased with time while mean age was stable. The prevalence of comorbidities increased, mortality remained stable (around 4%), but VF, ischemic stroke, and ARF increased with time. Compared to patients with HFrEF, HFpEF patients were 2 years older, more likely to be females, suffered from more cardio-metabolic risk factors, and had a higher prevalence of cardiovascular diseases. However, HFpEF patients were less likely to die [adjusted OR = 0.635 (0.601-0.670)] or develop VT [adjusted OR = 0.749 (0.703-0.797)], VF [adjusted OR = 0.866 (0.798-0.940)], ischemic stroke [adjusted OR = 0.871 [0.776-0.977)], and CS [adjusted OR = 0.549 (0.522-0.577)], but more likely to develop AF [adjusted OR = 1.121 (1.078-1.166)]. HFpEF patients were more likely to get PCI but less likely to get thrombolysis or CABG. Total charges per stay increased by at least 2-fold in both groups. There was a slight temporal reduction over the study period in the LoS of the HFpEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While hospitalizations for STEMI in patients with diabetes and HFpEF followed an upward trend, we observed a temporal decrease in those with HFrEF. Mortality was unchanged in both HF groups despite the temporal increase in risk factors. Nevertheless, HFpEF patients had lower in-hospital mortality and cardiovascular events, except for AF.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphys.2022.803092","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:13:02Z","timestamp":1643872382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Temporal Trends in Outcomes of ST-Elevation Myocardial Infarction Patients With Heart Failure and Diabetes"],"prefix":"10.3389","volume":"13","author":[{"given":"Bassem","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Dargham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jassim","family":"Al Suwaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Abi Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/1741826711409324","article-title":"Cause-specific mortality in diabetes: recent changes in trend mortality.","volume":"19","author":"Abi Khalil","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/JAHA.114.001090","article-title":"In-hospital mortality among patients with type 2 diabetes mellitus and acute myocardial infarction: results from the national inpatient sample, 2000-2010.","volume":"2014","author":"Ahmed","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"B3","year":"2021","journal-title":"Overview of the National (Nationwide) Inpatient Sample (NIS) Healthcare Cost and Utilization Project (HCUP)."},{"key":"B4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCHEARTFAILURE.112.000180","article-title":"Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population.","volume":"6","author":"Allen","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10840-019-00623-x","article-title":"Heart failure as a substrate and trigger for ventricular tachycardia.","volume":"56","author":"Alvarez","year":"2019","journal-title":"J. Interv. Card Electrophysiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4330\/wjc.v9.i5.407","article-title":"Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk.","volume":"9","author":"Cahill","year":"2017","journal-title":"World J. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s00392-019-01477-z","article-title":"Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.","volume":"108","author":"Chen","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"B8","article-title":"Global, regional, and national burden of ischemic heart disease and its attributable risk factors, 1990-2017: results from the global Burden of Disease Study 2017.","author":"Dai","year":"2020","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41598-018-19507-7","article-title":"Gender-related differences in heart failure with preserved ejection fraction.","volume":"8","author":"Duca","year":"2018","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update.","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med. Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.jacc.2003.05.012","article-title":"Gender differences in advanced heart failure: insights from the BEST study.","volume":"42","author":"Ghali","year":"2003","journal-title":"J. Am. Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijcard.2018.02.007","article-title":"Atrial fibrillation and heart failure with preserved ejection fraction: Insights on a unique clinical phenotype from a nationally-representative United States cohort.","volume":"266","author":"Goyal","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ. Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association.","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"crossref","first-page":"7839101","DOI":"10.1155\/2017\/7839101","article-title":"Macrovascular Complications in Patients with Diabetes and Prediabetes.","volume":"2017","author":"Huang","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/ehjqcco\/qcz022","article-title":"It\u2019s not ageing, stupid: why population ageing won\u2019t bankrupt health systems.","volume":"5","author":"Jayawardana","year":"2019","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/clc.22745","article-title":"Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry.","volume":"40","author":"Jeger","year":"2017","journal-title":"Clin. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1001\/jama.1983.03340210040022","article-title":"Manifestations of coronary disease predisposing to stroke. The Framingham study.","volume":"250","author":"Kannel","year":"1983","journal-title":"Jama"},{"key":"B21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ahj.2012.12.005","article-title":"Incidence of heart failure and mortality after acute coronary syndromes.","volume":"165","author":"Kaul","year":"2013","journal-title":"Am. Heart J."},{"key":"B22","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure.","volume":"40","author":"Lam","year":"2019","journal-title":"Eur. Heart J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.","volume":"39","author":"Lam","year":"2018","journal-title":"Eur. Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijcard.2018.02.117","article-title":"Impact of end stage renal disease on in-hospital outcomes of patients with systolic and diastolic heart failure (insights from the Nationwide Inpatient Sample 2010 to 2014).","volume":"266","author":"Lemor","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10741-020-10012-6","article-title":"Diabetes-related cardiovascular and economic burden in patients hospitalized for heart failure in the US: a recent temporal trend analysis from the National Inpatient Sample.","volume":"26","author":"Mekhaimar","year":"2021","journal-title":"Heart Fail Rev."},{"key":"B26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart Failure With Reduced Ejection Fraction: A Review.","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2337\/diacare.25.3.482","article-title":"The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes.","volume":"25","author":"Nichols","year":"2002","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update.","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction.","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr. Heart Fail Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies.","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur. Heart J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.114.008720","article-title":"Global and regional patterns in cardiovascular mortality from 1990 to 2013.","volume":"132","author":"Roth","year":"2015","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ccep.2017.07.010","article-title":"Heart Failure and Sudden Cardiac Death.","volume":"9","author":"Saour","year":"2017","journal-title":"Card Electrophysiol. Clin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1038\/s41598-021-87320-w","article-title":"Mortality and socio-economic outcomes among patients hospitalized for stroke and diabetes in the US: a recent analysis from the National Inpatient Sample.","volume":"11","author":"Tabbalat","year":"2021","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"612","DOI":"10.2337\/diacare.28.3.612","article-title":"The association between glucose abnormalities and heart failure in the population-based Reykjavik study.","volume":"28","author":"Thrainsdottir","year":"2005","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1671-5411.2014.01.002","article-title":"Development and course of heart failure after a myocardial infarction in younger and older people.","volume":"11","author":"Torabi","year":"2014","journal-title":"J. Geriatr. Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction.","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","article-title":"A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).","volume":"38","author":"Urbich","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1161\/CIR.0000000000000525","article-title":"Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association.","volume":"136","author":"van Diepen","year":"2017","journal-title":"Circulation"},{"key":"B39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/eurjhf\/hfr172","article-title":"Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study.","volume":"14","author":"Vemmos","year":"2012","journal-title":"Eur. J. Heart Fail"},{"key":"B40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.15420\/aer.2018.76.2","article-title":"Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology and Novel Therapeutic Opportunities.","volume":"8","author":"Vyas","year":"2019","journal-title":"Arrhythm. Electrophysiol. Rev."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.803092\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:13:11Z","timestamp":1643872391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.803092\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":40,"alternative-id":["10.3389\/fphys.2022.803092"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.803092","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"article-number":"803092"}}